Michael Makris

List of Publications by Year in Descending Order

370 papers	10,163 citations	50 h-index	91 g-index
433 ext. papers	12,022 ext. citations	6.1 avg, IF	6.32 L-index

#	Paper	IF	Citations
370	Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT).. *Lancet Regional Health - Europe, The*, **2022**, 12, 100274		1
369	Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model.. *Clinical and Translational Allergy*, **2022**, 12, e12128	5.2	3
368	Adrenaline autoinjector is underprescribed in typical cold urticaria patients.. *Allergy: European Journal of Allergy and Clinical Immunology*, **2022**,	9.3	1
367	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC.. *Haemophilia*, **2022**,	3.3	2
366	Long COVID and neuropsychiatric manifestations (Review).. *Experimental and Therapeutic Medicine*, **2022**, 23, 363	2.1	2
365	Suicidality and COVID-19: Suicidal ideation, suicidal behaviors and completed suicides amidst the COVID-19 pandemic (Review).. *Experimental and Therapeutic Medicine*, **2022**, 23, 107	2.1	4
364	Development and validation of combined symptom-medication scores for allergic rhinitis.. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**,	9.3	6
363	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. *Blood Advances*, **2021**,	7.8	1
362	Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA LEN position paper. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**,	9.3	2
361	Vaccine-induced immune thrombotic thrombocytopenia. *Lancet Haematology,the*, **2021**,	14.6	23
360	Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**,	9.3	2
359	Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?. *Lancet, The*, **2021**, 398, 1801	40	3
358	Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).. *Clinical and Applied Thrombosis/Hemostasis*, **2021**, 27, 10760296211066945	3.3	1
357	Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. *Haemophilia*, **2021**, 27, 515-518	3.3	6
356	Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities. *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry*, **2021**, 20, 39-50	2	1
355	Digital Health Europe (DHE) Twinning on severe asthma-kick-off meeting report. *Journal of Thoracic Disease*, **2021**, 13, 3215-3225	2.6	
354	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA LEN consensus. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 2354-2366	9.3	10

353	Piperacillin-Tazobactam Hypersensitivity: A Large, Multicenter Analysis. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 2001-2009	5.4	1
352	Disruptive technology and hemophilia care: The multiple impacts of emicizumab. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12508	5.1	3
351	Viral hepatitis in haemophilia: historical perspective and current management. *British Journal of Haematology*, **2021**, 195, 174-185	4.5	7
350	Adoption of emicizumab (Hemlibra) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. *Haemophilia*, **2021**, 27, 736-743	3.3	3
349	How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. *World Allergy Organization Journal*, **2021**, 14, 100542	5.2	3
348	Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12529	5.1	39
347	Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 3041-3052	9.3	5
346	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 168-190	9.3	21
345	Management of comorbidities in haemophilia. *Haemophilia*, **2021**, 27 Suppl 3, 37-45	3.3	7
344	The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 816-830	9.3	18
343	Management of COVID-19-associated coagulopathy in persons with haemophilia. *Haemophilia*, **2021**, 27, 41-48	3.3	6
342	Efficacy of a Quail Eggs-Based Dietary Supplement for Allergic Rhinitis: Results of a Single-Arm Trial. *Journal of Dietary Supplements*, **2021**, 18, 17-30	2.3	1
341	Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. *Allergy, Asthma and Immunology Research*, **2021**, 13, 545-559	5.3	11
340	Making treatment decisions in hemophilia based on available safety data. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1138-1139	15.4	1
339	Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2007-2013	15.4	53
338	Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2263-2267	15.4	6
337	Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. *Haemophilia*, **2021**, 27, 932-937	3.3	3
336	Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. *New England Journal of Medicine*, **2021**, 385, 1680-1689	59.2	156

335	Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK□□a multicentre observational study. *British Journal of Haematology*, **2021**,	4.5	1
334	The international EAACI/GA□LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**,	9.3	50
333	Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. *Haemophilia*, **2021**, 27, 967-973	3.3	5
332	Generalized Bullous Fixed Drug Eruption to Fluconazole with Positive Patch Testing and Confirmed Tolerance to Itraconazole. *Iranian Journal of Allergy, Asthma and Immunology*, **2021**, 20, 255-259	1.1	0
331	Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis.. *Clinical and Translational Allergy*, **2021**, 11, e12089	5.2	1
330	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. *Clinical and Translational Allergy*, **2020**, 10, 62	5.2	13
329	The World Federation of Hemophilia Annual Global Survey 1999-2018. *Haemophilia*, **2020**, 26, 591-600	3.3	18
328	Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. *Haematologica*, **2020**, 105, 2038-2043	6.6	11
327	Staying updated on COVID-19: Social media to amplify science in thrombosis and hemostasis. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 722-726	5.1	2
326	Gene therapy 1□□ in haemophilia: effective and safe, but with many uncertainties. *Lancet Haematology,the*, **2020**, 7, e186-e188	14.6	3
325	Immunotherapy in allergic diseases - improved understanding and innovation for enhanced effectiveness. *Current Opinion in Immunology*, **2020**, 66, 1-8	7.8	5
324	Definition, aims, and implementation of GA LEN/HAEi Angioedema Centers of Reference and Excellence. *Allergy: European Journal of Allergy and Clinical Immunology*, **2020**, 75, 2115-2123	9.3	10
323	Time-Dependent Effects in Chronic Urticaria: A Time-Series Perspective of Omalizumab Treatment. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2020**, 20, 1726-1739	2.2	1
322	The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. *World Allergy Organization Journal*, **2020**, 13, 100475	5.2	8
321	"Whole" vs. "fragmented" approach to EAACI pollen season definitions: A multicenter study in six Southern European cities. *Allergy: European Journal of Allergy and Clinical Immunology*, **2020**, 75, 1659-1671	9.3	7
320	Increased Basal Blood Histamine Levels in Patients with Self-Reported Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs. *International Archives of Allergy and Immunology*, **2020**, 181, 24-30	3.7	0
319	Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. *Thrombosis Research*, **2020**, 196, 21-24	8.2	
318	The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases. *Current Opinion in Allergy and Clinical Immunology*, **2020**, 20, 367-373	3.3	12

317	Evolution of Haemophilia Care in Europe: 10 years of the principles of care. *Orphanet Journal of Rare Diseases*, **2020**, 15, 184	4.2	6
316	Deciphering the Genetics of Primary Angioedema with Normal Levels of C1 Inhibitor. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
315	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. *Haemophilia*, **2020**, 26, 966-974	3.3	3
314	Management of bleeding and procedures in patients on antiplatelet therapy. *Blood Reviews*, **2020**, 39, 100619	11.1	8
313	Ligelizumab for Chronic Spontaneous Urticaria. *New England Journal of Medicine*, **2019**, 381, 1321-1332	59.2	102
312	Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study. *Allergy: European Journal of Allergy and Clinical Immunology*, **2019**, 74, 2427-2436	9.3	61
311	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 528-541	5.1	11
310	How to discuss gene therapy for haemophilia? A patient and physician perspective. *Haemophilia*, **2019**, 25, 545-557	3.3	29
309	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 135-143.e6	11.5	57
308	Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 12-14	5.1	4
307	Inherited Thrombophilia and Pregnancy Complications: Should We Test?. *Seminars in Thrombosis and Hemostasis*, **2019**, 45, 50-60	5.3	14
306	Real-life experience in switching to new extended half-life products at European haemophilia centres. *Haemophilia*, **2019**, 25, 946-952	3.3	20
305	Emicizumab and thrombosis: The story so far. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1269-1272	5.4	31
304	Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). *Patient Preference and Adherence*, **2019**, 13, 969-979	2.4	4
303	Reply to Comment on: Inherited Thrombophilia and Pregnancy Complications: Should We Test?. *Seminars in Thrombosis and Hemostasis*, **2019**, 45, 555-556	5.3	2
302	Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS). *Psychology Research and Behavior Management*, **2019**, 12, 741-752	3.8	3
301	Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. *Annals of Internal Medicine*, **2019**, 171, 540-546	8	115
300	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. *HemaSphere*, **2019**, 3, e286	0.3	23

299	Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors: a systematic literature review. *Blood Coagulation and Fibrinolysis*, **2019**, 30, 309-323	1	
298	Haemophilia and ageing. *British Journal of Haematology*, **2019**, 184, 712-720	4.5	14
297	Comparative analysis of marketed factor VIII products: comment. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 232-233	15.4	1
296	Measurement of extended half-life recombinant factor IX products in clinical practice. *International Journal of Laboratory Hematology*, **2019**, 41, e46-e49	2.5	8
295	Hemophilia gene therapy is effective and safe. *Blood*, **2018**, 131, 952-953	2.2	3
294	Severe Wound Healing Impairment in a Patient with Dysfibrinogenaemia. *Thrombosis and Haemostasis*, **2018**, 118, 430-432	7	3
293	Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. *Haemophilia*, **2018**, 24, 104-112	3.3	9
292	Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. *Haemophilia*, **2018**, 24, 344-347	3.3	55
291	The reversal of anticoagulation in clinical practice . *Clinical Medicine*, **2018**, 18, 314-319	1.9	16
290	Retrospective evaluation of non-steroidal anti-inflammatory drug-induced hypersensitivity reactions reported in a tertiary hospital allergy unit in Greece. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO1-4-41	0	
289	Inherited Platelet Defects **2018**, 133-152		
288	The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 2530-2533	15.4	29
287	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. *Research and Practice in Thrombosis and Haemostasis*, **2018**, 2, 535-548	5.1	30
286	Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. *British Journal of Haematology*, **2017**, 178, 20-31	4.5	8
285	Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories. *International Journal of Laboratory Hematology*, **2017**, 39, 350-358	2.5	5
284	First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties. *Haemophilia*, **2017**, 23, 654-659	3.3	21
283	von Willebrand disease and extra-intestinal angiodysplasia. *Haemophilia*, **2017**, 23, e354-e355	3.3	2
282	The current state of adverse event reporting in hemophilia. *Expert Review of Hematology*, **2017**, 10, 161-168	2.8	1

281	New findings on inhibitor development: from registries to clinical studies. *Haemophilia*, **2017**, 23 Suppl 1, 4-13	3.3	15
280	Inhibitor development in haemophilia. *Haemophilia*, **2017**, 23 Suppl 1, 3	3.3	7
279	Thrombosis in Inherited Fibrinogen Disorders. *Transfusion Medicine and Hemotherapy*, **2017**, 44, 70-76	4.2	39
278	Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1878-1881	15.4	9
277	Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories. *International Journal of Laboratory Hematology*, **2017**, 39, 653-662	2.5	9
276	The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate. *Haemophilia*, **2017**, 23, e469-e470	3.3	13
275	Cross sectional questionnaire-based internet study: Self-perception and clinical course of drug allergy in Greece. *Allergology International*, **2017**, 66, 59-63	4.4	5
274	Why is it so difficult to show that prothrombin complex concentrates are superior to fresh-frozen plasma for warfarin reversal?. *Blood Transfusion*, **2017**, 15, 277-278	3.6	1
273	In Vivo Diagnostic Procedures for IgE-Mediated Allergic Disorders. *Methods in Pharmacology and Toxicology*, **2017**, 433-472	1.1	1
272	Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 1668-72	15.4	6
271	Acquired Inhibitors of Coagulation **2016**, 124-133		
270	Von Willebrand Disease **2016**, 94-112		
269	Prophylaxis in von Willebrand Disease: Coming of Age?. *Seminars in Thrombosis and Hemostasis*, **2016**, 42, 498-506	5.3	17
268	Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). *Blood*, **2016**, 128, 207-207	2.2	
267	Von Willebrand factor activity assay errors. *Haemophilia*, **2016**, 22, e74-6	3.3	3
266	Congenital macrothrombocytopenia is a heterogeneous disorder in India. *Haemophilia*, **2016**, 22, 570-82	3.3	6
265	Choosing and using non-steroidal anti-inflammatory drugs in haemophilia. *Haemophilia*, **2016**, 22, 179-187	3.3	14
264	Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. *Allergy: European Journal of Allergy and Clinical Immunology*, **2016**, 71, 1210-8	9.3	65

263	FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. *Haemophilia*, **2016**, 22, e36-8	3.3	10
262	Alternaria and Cladosporium calendar of Western Thrace: Relationship with allergic rhinitis symptoms. *Laryngoscope*, **2016**, 126, E51-6	3.6	13
261	Is fresh frozen plasma as good as prothrombin complex concentrate for vitamin K antagonist reversal in acute intracerebral hemorrhage?. *Annals of Neurology*, **2016**, 79, 331-2	9.4	1
260	Quality control of point of care INR devices is essential. *BMJ, The*, **2016**, 353, i2019	5.9	1
259	Basic Principles Underlying Coagulation **2016**, 1-11		
258	Quantitative Platelet Disorders **2016**, 134-159		
257	Qualitative Platelet Disorders **2016**, 160-171		
256	Thrombotic Microangiopathies **2016**, 183-194		
255	Myeloproliferative Neoplasms: Thrombosis and Hemorrhage **2016**, 210-228		
254	Arterial Thrombosis **2016**, 229-239		
253	Anticoagulation: Heparins and Vitamin K Antagonists **2016**, 240-252		
252	The Direct Oral Anticoagulants **2016**, 253-268		
251	Laboratory Tests of Hemostasis **2016**, 12-26		
250	Cardiovascular Medicine **2016**, 282-298		
249	Cardiothoracic Surgery **2016**, 299-313		1
248	Hepatology **2016**, 329-339		
247	Obstetrics, Contraception, and Estrogen Replacement **2016**, 379-392		
246	Intensive and Critical Care **2016**, 414-432		

245	Transfusion **2016**, 433-443		
244	Molecular Diagnostic Approaches to Hemostasis **2016**, 27-41		1
243	Tests of Platelet Function **2016**, 42-62		
242	Evaluation of the Bleeding Patient **2016**, 63-78		
241	Hemophilia A and B **2016**, 79-93		1
240	The Rarer Inherited Coagulation Disorders **2016**, 113-123		
239	Hemophilia A treatment: disruptive technology ahead. *Blood*, **2016**, 127, 1623-4	2.2	0
238	Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. *Haematologica*, **2016**, 101, 1170-1179	6.6	89
237	Safety surveillance in haemophilia and allied disorders. *Journal of Internal Medicine*, **2016**, 279, 515-23	10.8	5
236	Comparable profiles of serum histamine and IgG4 levels in allergic beekeepers. *Allergy: European Journal of Allergy and Clinical Immunology*, **2015**, 70, 457-60	9.3	14
235	The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. *Haemophilia*, **2015**, 21, 338-42	3.3	30
234	Successful rapid desensitization to imiglucerase in an adult patient with Gaucher disease and documented IgE-mediated hypersensitivity. *Journal of Allergy and Clinical Immunology: in Practice*, **2015**, 3, 624-6	5.4	4
233	The clinical significance of the pollen calendar of the Western Thrace/northeast Greece region in allergic rhinitis. *International Forum of Allergy and Rhinology*, **2015**, 5, 1156-63	6.3	11
232	Inhibitor development in non-severe haemophilia across Europe. *Thrombosis and Haemostasis*, **2015** , 114, 670-5	7	11
231	Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. *Thrombosis and Haemostasis*, **2015**, 113, 968-75	7	89
230	Is the continued use of UK plasma sourced cryoprecipitate justified?. *British Journal of Haematology* , **2015**, 168, 908-10	4.5	
229	Management of peri-operative anti-thrombotic therapy. *Anaesthesia*, **2015**, 70 Suppl 1, 58-67, e21-3	6.6	38
228	Seasonal variations of allergenic pollen in a Mediterranean region - Alexandroupolis, north-east Greece. *Annals of Agricultural and Environmental Medicine*, **2015**, 22, 685-9	1.4	3

227	Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. *Haemophilia*, **2014**, 20, 200-6	3.3	15
226	Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. *Journal of Hepatology*, **2014**, 60, 39-45	13.4	42
225	Reply to: Pityriasis rosea and pityriasis rosea-like eruptions. *Journal of the American Academy of Dermatology*, **2014**, 70, 196-7	4.5	1
224	Viral Hepatitis and Hemophilia **2014**, 263-271		
223	Food protein-induced enterocolitis syndrome: pitfalls in the diagnosis. *Pediatric Allergy and Immunology*, **2014**, 25, 622-9	4.2	9
222	Prothrombin complex concentrate for non-vitamin K oral anticoagulant reversal: good enough for now?. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1425-7	15.4	6
221	Enhancing haemophilia care through registries. *Haemophilia*, **2014**, 20 Suppl 4, 121-9	3.3	13
220	The use of biologicals in cutaneous allergies - present and future. *Current Opinion in Allergy and Clinical Immunology*, **2014**, 14, 409-16	3.3	9
219	The European Haemophilia Network (EUHANET). *Blood Transfusion*, **2014**, 12 Suppl 3, s515-8	3.6	5
218	Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 1655-62	15.4	47
217	Pharmacotherapy of chronic spontaneous urticaria. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 2511-9	4	10
216	Key regulators of sensitization and tolerance: GM-CSF, IL-10, TGF- and the Notch signaling pathway in adjuvant-free experimental models of respiratory allergy. *International Reviews of Immunology*, **2013**, 32, 307-23	4.6	3
215	Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. *Annals of Allergy, Asthma and Immunology*, **2013**, 111, 542-7	3.2	27
214	Guideline on the management of bleeding in patients on antithrombotic agents. *British Journal of Haematology*, **2013**, 160, 35-46	4.5	155
213	The World Federation of Hemophilia guideline on management of haemophilia. *Haemophilia*, **2013**, 19, 1	3.3	12
212	Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. *Haematologica*, **2013**, 98, 1980-7	6.6	35
211	Anxiety and depression seem less common in patients with autoreactive chronic spontaneous urticaria. *Clinical and Experimental Dermatology*, **2013**, 38, 870-3	1.8	6
210	Vaccination induced neutropenia. *International Journal of Laboratory Hematology*, **2013**, 35, e33	2.5	5

209	Update to UKHCDO guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease. *Haemophilia*, **2013**, 19, e191-2	3.3	5
208	Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria. *Dermatology*, **2013**, 226, 371-9	4.4	29
207	The impact of nail disorders on quality of life. *European Journal of Dermatology*, **2013**, 23, 366-71	0.8	28
206	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. *Thrombosis and Haemostasis*, **2013**, 109, 16-23	7	52
205	Atopic Dermatitis, food allergy and dietary interventions. A tale of controversy. *Anais Brasileiros De Dermatologia*, **2013**, 88, 839-41	1.6	4
204	Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy. *Blood Transfusion*, **2013**, 11, 500-5	3.6	16
203	How I treat inhibitors in haemophilia. *Haemophilia*, **2012**, 18 Suppl 4, 48-53	3.3	14
202	Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. *Haemophilia*, **2012**, 18, 881-7	3.3	21
201	Clotting factor concentrate switching and inhibitor development in hemophilia A. *Blood*, **2012**, 120, 720-7	12.2	37
200	Parvovirus transmission by blood products - a cause for concern?. *British Journal of Haematology*, **2012**, 159, 385-93	4.5	29
199	Exposure of immunologically naive laboratory rodents to antigen via the airways. Where does tolerance stop and sensitization begin?. *Clinical and Experimental Allergy*, **2012**, 42, 1552-65	4.1	7
198	Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic load. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 20-2	15.4	11
197	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. *Haemophilia*, **2012**, 18, e173-87	3.3	71
196	Prophylaxis in haemophilia should be life-long. *Blood Transfusion*, **2012**, 10, 165-8	3.6	56
195	A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease. *Thrombosis Research*, **2011**, 127, 341-4	8.2	12
194	EUHASS: The European Haemophilia Safety Surveillance system. *Thrombosis Research*, **2011**, 127 Suppl 2, S22-5	8.2	61
193	Guidelines on oral anticoagulation with warfarin - fourth edition. *British Journal of Haematology*, **2011**, 154, 311-24	4.5	399
192	Pharmacokinetics of Optivate( ), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. *Haemophilia*, **2011**, 17, 185-90	3.3	6

191	Experience with Optivate , a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery. *Haemophilia*, **2011**, 17, 428-32	3.3	4
190	Clinical assessment of Optivate , a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A. *Haemophilia*, **2011**, 17, 456-62	3.3	10
189	More on: enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 613-614	15.4	
188	Concentrate-related inhibitor risk: is a difference always real?. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2176-9	15.4	25
187	The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies. *International Journal of Laboratory Hematology*, **2011**, 33, 154-8	2.5	44
186	The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal. *International Journal of Laboratory Hematology*, **2011**, 33, 212-8	2.5	7
185	The phenotypic and genetic assessment of antithrombin deficiency. *International Journal of Laboratory Hematology*, **2011**, 33, 227-37	2.5	44
184	Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. *Blood*, **2011**, 118, 2267-2267	2.2	
183	Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders. *Haemophilia*, **2010**, 16, 305-15	3.3	17
182	Biovigilance and pharmacovigilance for haemophilia. *Haemophilia*, **2010**, 16 Suppl 5, 17-21	3.3	9
181	The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. *British Journal of Haematology*, **2010**, 148, 15-25	4.5	146
180	Clinical guidelines for testing for heritable thrombophilia. *British Journal of Haematology*, **2010**, 149, 209-20	4.5	349
179	Phenotypic approaches to gene mapping in platelet function disorders. *Hamostaseologie*, **2010**, 30, 29-38	1.9	38
178	Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. *International Archives of Allergy and Immunology*, **2010**, 151, 38-45	3.7	34
177	Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. *Cochrane Database of Systematic Reviews*, **2010**, CD004449		29
176	Evaluation of the Bleeding Patient **2010**, 48-60		
175	Hemophilia A and B **2010**, 61-72		
174	Disseminated Intravascular Coagulation and other Microangiopathies **2010**, 123-134		

173	Anticoagulation **2010**, 164-176		
172	Hepatology **2010**, 218-226		
171	Transfusion **2010**, 287-296		
170	Qualitative Platelet Disorders **2010**, 115-122		
169	Quantitative Platelet Disorders **2010**, 96-114		
168	Basic Principles Underlying Coagulation **2010**, 1-6		2
167	Laboratory Tests of Hemostasis **2010**, 7-16		3
166	Laboratory Evaluation and Thrombophilia **2010**, 17-24		
165	Molecular Diagnostic Approaches to Hemostasis **2010**, 25-36		1
164	Tests of Platelet Function **2010**, 37-47		
163	Temporal relationship of allergic rhinitis with asthma and other co-morbidities in a Mediterranean country: a retrospective study in a tertiary reference allergy clinic. *Allergologia Et Immunopathologia*, **2010**, 38, 246-53	1.9	9
162	Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization. *Allergy: European Journal of Allergy and Clinical Immunology*, **2010**, 65, 925-6	9.3	10
161	Hepatitis and Hemophilia **2010**, 215-221		
160	Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. *Journal of Thrombosis and Thrombolysis*, **2010**, 29, 171-81	5.1	52
159	Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1994-2000	15.4	145
158	Src family kinases are essential for primary aggregation by G(i) -coupled receptors. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2273-82	15.4	21
157	Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin. *European Journal of Haematology*, **2009**, 82, 208-12	3.8	27
156	The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. *International Journal of Laboratory Hematology*, **2009**, 31, 189-98	2.5	22

155	Optimizing warfarin reversal--an ex vivo study. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1123-7	15.4	24
154	Pregnancy outcome in women with factor V Leiden and recurrent miscarriage. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2009**, 116, 995-8	3.7	16
153	Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. *Thrombosis Research*, **2009**, 123, 895-901	8.2	44
152	Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. *Reproductive BioMedicine Online*, **2009**, 19, 216-20	4	2
151	Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. *Blood*, **2009**, 113, 4110-3	2.2	59
150	Thrombophilia: grading the risk. *Blood*, **2009**, 113, 5038-9	2.2	21
149	Is VIII worse than IX?. *Blood*, **2009**, 114, 750-1	2.2	28
148	Acute generalized exanthematous pustulosis (AGEP) triggered by a spider bite. *Allergology International*, **2009**, 58, 301-3	4.4	28
147	Evaluation of a new venom-based clotting assay of protein C. *International Journal of Laboratory Hematology*, **2008**, 30, 437-43	2.5	10
146	Thrombin generation testing in routine clinical practice: are we there yet?. *British Journal of Haematology*, **2008**, 142, 889-903	4.5	164
145	Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. *British Journal of Haematology*, **2008**, 142, 946-52	4.5	36
144	Paracetamol/acetaminophen usage in haemophilia: more caution needed?. *Haemophilia*, **2008**, 14, 434-5	3.3	5
143	Liver transplantation for factor XI deficiency: cure before diagnosis. *Haemophilia*, **2008**, 14, 649-50	3.3	2
142	Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. *Haemophilia*, **2008**, 14, 671-84	3.3	159
141	Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. *Thrombosis and Haemostasis*, **2008**, 100, 350-355	7	66
140	A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. *American Journal of Medicine*, **2008**, 121, 632-6	2.4	124
139	An interpretative phenomenological analysis of adaptation to recurrent venous thrombosis and heritable thrombophilia: the importance of multi-causal models and perceptions of primary and secondary control. *Journal of Health Psychology*, **2008**, 13, 776-84	3.1	9
138	Altitude and coagulation activation: does going high provoke thrombosis?. *Acta Haematologica*, **2008**, 119, 156-7	2.7	9

137	Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. *Blood Coagulation and Fibrinolysis*, **2008**, 19, 183-9	1	75
136	Protein C deficiency screening using a thrombin generation assay □An upgrade. *Thrombosis and Haemostasis*, **2007**, 98, 691-692	7	4
135	Hyperhomocysteinemia in women with advanced breast cancer. *International Journal of Laboratory Hematology*, **2007**, 29, 421-5	2.5	30
134	Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill. *Haemophilia*, **2007**, 13, 93-7	3.3	34
133	Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1624-9	15.4	35
132	Fatal spontaneous thrombosis of a cerebral arteriovenous malformation in a young patient with a rare heterozygous prothrombin gene mutation. Case report. *Journal of Neurosurgery: Pediatrics*, **2007**, 106, 143-6	2.1	4
131	Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. *Blood*, **2007**, 109, 1870-7	2.2	501
130	Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. *Blood*, **2007**, 109, 3667-71	2.2	72
129	Hyperhomocysteinemia and venous thrombosis. *Seminars in Hematology*, **2007**, 44, 70-6	4	33
128	Cognitive appraisals and psychological distress following venous thromboembolic disease: an application of the theory of cognitive adaptation. *Social Science and Medicine*, **2006**, 63, 2395-406	5.1	18
127	Gastrointestinal bleeding in von Willebrand disease. *Thrombosis Research*, **2006**, 118 Suppl 1, S13-7	8.2	46
126	Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. *Thrombosis and Haemostasis*, **2006**, 95, 600-605	7	140
125	Pattern of sensitization to honeybee venom in beekeepers: a 5-year prospective study. *Allergy and Asthma Proceedings*, **2006**, 27, 383-7	2.6	6
124	Uncertain times for research on hemophilia and allied disorders. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 683-683	15.4	1
123	Between-batch variation of calibrator activity can significantly influence fluorogenic measurement of thrombin generation. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2514-6	15.4	6
122	Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. *Haemophilia*, **2006**, 12, 473-8	3.3	23
121	Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (Spontaneous HIT)□. *Blood*, **2006**, 108, 1047-1047	2.2	3
120	A Novel Protac□ -Modified Thrombin Generation Assay To Identify Individuals at Higher Thrombotic Risk.. *Blood*, **2006**, 108, 1472-1472	2.2	1

119	Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.. *Blood*, **2006**, 108, 876-876	2.6	
118	Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). *Journal of Thrombosis and Haemostasis*, **2005**, 3, 459-64	15.4	147
117	Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttal. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 818-9; author reply 819	15.4	8
116	Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia. *British Journal of Haematology*, **2005**, 130, 297-309	4.5	113
115	Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1992-7	9.4	75
114	UKHCDO Acquired Haemophilia Study: A Complete National Cohort.. *Blood*, **2005**, 106, 322-322	2.2	1
113	Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. *British Journal of Haematology*, **2004**, 127, 209-13	4.5	32
112	Hereditary thrombophilia and fetal loss: a prospective follow-up study. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 592-6	15.4	71
111	Familial thrombophilia and lifetime risk of venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 1526-32	15.4	71
110	Unconventional diagnosis of Normandy-type von Willebrand's disease in a blood donor. *Transfusion Medicine*, **2004**, 14, 181-4	1.3	
109	SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria?. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 271-4	15.4	29
108	Bleeding small bowel angiodysplasia in association with aortic stenosis: a role for combined wireless capsule endoscopy and push enteroscopy?. *Journal of Clinical Gastroenterology*, **2004**, 38, 836-7	3	0
107	Systematic review of the management of patients with haemophilia A and inhibitors. *Blood Coagulation and Fibrinolysis*, **2004**, 15 Suppl 1, S25-7	1	7
106	Management of excessive anticoagulation or bleeding. *Seminars in Vascular Medicine*, **2003**, 3, 279-84		13
105	Evaluation of the Roche LightCycler. *Blood Coagulation and Fibrinolysis*, **2003**, 14, 499-503	1	12
104	Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. *Blood*, **2003**, 102, 2085-92	2.2	147
103	Unsuspected haemophilia in children with a single swollen joint. *BMJ, The*, **2003**, 326, 151-2	5.9	
102	Immunization of patients with bleeding disorders. *Haemophilia*, **2003**, 9, 541-6	3.3	31

101	Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 1112-4	15.4	18
100	Bone marrow biopsy related haemorrhage and low molecular weight heparin. *British Journal of Haematology*, **2003**, 123, 562	4.5	7
99	Reply to escobar. *British Journal of Haematology*, **2002**, 118, 926-926	4.5	1
98	Axillary vein thrombosis in a healthy donor following platelet apheresis. *British Journal of Haematology*, **2002**, 116, 390-1	4.5	9
97	The use of oral vitamin K for reversal of over-warfarinization. *British Journal of Haematology*, **2002**, 116, 237	4.5	5
96	Kilt syndrome?. *British Journal of Haematology*, **2002**, 118, 1199-200	4.5	24
95	Recurrent miscarriage: aetiology, management and prognosis. *Human Reproduction Update*, **2002**, 8, 463-81	15.8	334
94	Reply to Escobar. *British Journal of Haematology*, **2002**, 118, 926-927	4.5	3
93	An evaluation of screening tests for defects in the protein C pathway: commercial kits lack sensitivity and specificity. *Blood Coagulation and Fibrinolysis*, **2002**, 13, 155-63	1	8
92	Air flight-related thrombosis: reality or hype?. *British Journal of Biomedical Science*, **2002**, 59, 2-3	1.6	
91	Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. *Thrombosis and Haemostasis*, **2002**, 88, 387-8	7	30
90	The management of coumarin-induced over-anticoagulation Annotation. *British Journal of Haematology*, **2001**, 114, 271-80	4.5	98
89	A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. *British Journal of Haematology*, **2001**, 115, 145-9	4.5	149
88	Failure of recombinant FVIIa as treatment for abdominal bleeding in acquired hemophilia. *American Journal of Hematology*, **2001**, 66, 67-68	7.1	5
87	Personal practice: An approach to investigation of easy bruising. *Archives of Disease in Childhood*, **2001**, 84, 488-91	2.2	7
86	The management of von Willebrand's disease-associated gastrointestinal angiodysplasia. *Blood Coagulation and Fibrinolysis*, **2001**, 12, 143-8	1	24
85	Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. *Haemophilia*, **2001**, 7, 339-45	3.3	25
84	Failure of recombinant FVIIa as treatment for abdominal bleeding in acquired hemophilia **2001**, 66, 67		1

83	Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. *British Journal of Haematology*, **2000**, 110, 135-8	4.5	13
82	Monthly haemoptysis in a woman with platelet storage pool disease. *International Journal of Laboratory Hematology*, **2000**, 22, 295-6		2
81	Hyperhomocysteinemia and thrombosis. *International Journal of Laboratory Hematology*, **2000**, 22, 133-43		47
80	Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway. *International Journal of Laboratory Hematology*, **2000**, 22, 351-4		3
79	Poor reversal of low molecular weight heparin by protamine. *British Journal of Haematology*, **2000**, 108, 884-5	4.5	35
78	Major Structural Defects in the Antithrombin Gene in Four Families with Type I Antithrombin Deficiency. *Thrombosis and Haemostasis*, **2000**, 83, 715-721	7	23
77	Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. *British Journal of Haematology*, **2000**, 111, 974-979	4.5	12
76	Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. *Blood*, **2000**, 95, 1935-41	2.2	21
75	Null Alleles Are not a Common Cause of Type 1 von Willebrand Disease in the British Population. *Thrombosis and Haemostasis*, **1999**, 82, 1373-1375	7	6
74	Retinal vein occlusion, the contraceptive pill and the prothrombin 20210A allele. *Eye*, **1999**, 13 (Pt 2), 269	4.4	1
73	Alternative models of delivery of anticoagulant services. *Seminars in Thrombosis and Hemostasis*, **1999**, 25, 33-6	5.3	1
72	Mesenteric infarction due to combined protein C deficiency and prothrombin 20210 defects. *Postgraduate Medical Journal*, **1999**, 75, 742-3	2	6
71	A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. *British Journal of Haematology*, **1999**, 104, 915-8	4.5	34
70	The common haemochromatosis mutation does not increase the risk of thrombosis in patients with factor V Leiden. *British Journal of Haematology*, **1999**, 105, 842-3	4.5	1
69	Spinal epidural haematoma in haemophilia A with inhibitors--efficacy of recombinant factor VIIa concentrate. *Haemophilia*, **1999**, 5, 209-12	3.3	15
68	Acute renal failure in acquired haemophilia following the use of high dose intravenous immunoglobulin. *Haemophilia*, **1999**, 5, 270-2	3.3	10
67	Norethisterone therapy for bleeding due to gastrointestinal telangiectases in Glanzmann's thrombasthenia. *British Journal of Haematology*, **1998**, 100, 594-6	4.5	3
66	Acute liver failure induced by alcohol and paracetamol in an HCV-infected haemophiliac. *British Journal of Haematology*, **1998**, 103, 891-3	4.5	8

65	A Novel Mutation in Intron K of the PROS1 Gene Causes Aberrant RNA Splicing and Is a Common Cause of Protein S Deficiency in a UK Thrombophilia Cohort. *Thrombosis and Haemostasis*, **1998**, 79, 1086-1091	7	15
64	Antithrombins Wibble and Wobble (T85M/K): Archetypal Conformational Diseases With In Vivo Latent-Transition, Thrombosis, and Heparin Activation. *Blood*, **1998**, 92, 2696-2706	2.2	1
63	Hyperhomocysteinemia is a risk factor for venous and arterial thrombosis. *British Journal of Haematology*, **1998**, 101 Suppl 1, 18-20	4.5	1
62	Factor V Leiden in Greek thrombophilia patients. *Blood Coagulation and Fibrinolysis*, **1997**, 8, 485-490	1	4
61	Interferon-alpha treatment and formation of factor VIII antibodies. *Annals of Internal Medicine*, **1997**, 126, 829; author reply 829-30	8	3
60	Familial thrombophilia: genetic risk factors and management. *Journal of Internal Medicine*, **1997**, 242, 9-15	10.8	35
59	The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. *British Journal of Haematology*, **1997**, 98, 660-1	4.5	21
58	Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy. *Thrombosis and Haemostasis*, **1997**, 77, 477-480	7	284
57	Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia. *Thrombosis and Haemostasis*, **1997**, 78, 1426-1429	7	117
56	Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. *Thrombosis and Haemostasis*, **1997**, 77, 477-80	7	69
55	Familial thrombophilia: genetic risk factors and management. *Journal of Internal Medicine Supplement*, **1997**, 740, 9-15		9
54	Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. *Thrombosis and Haemostasis*, **1997**, 78, 1426-9	7	18
53	Increased fetal loss in women with heritable thrombophilia. *Lancet, The*, **1996**, 348, 913-6	40	550
52	Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. *Blood*, **1996**, 88, 1700-1707	2.2	20
51	The natural history of chronic hepatitis C in haemophiliacs. *British Journal of Haematology*, **1996**, 94, 746-53	4.5	152
50	Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. *Blood*, **1996**, 88, 1700-1707	2.2	18
49	Warfarin Induced Skin Necrosis Associated with Activated Protein C Resistance. *Thrombosis and Haemostasis*, **1996**, 75, 523-524	7	15
48	Characterisation of Type 2N von Willebrand Disease Using Phenotypic and Molecular Techniques. *Thrombosis and Haemostasis*, **1996**, 75, 959-964	7	26

47	Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. *Blood*, **1995**, 85, 1259-1262	2.2	69
46	Peripheral mononuclear cells of haemophiliacs with chronic liver disease are infected with replicating hepatitis C virus. *British Journal of Haematology*, **1994**, 87, 215-7	4.5	11
45	Increased soluble IL-2 receptor levels in HCV-infected haemophiliacs: a possible indicator of liver disease severity. *British Journal of Haematology*, **1994**, 87, 419-21	4.5	13
44	Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. *British Journal of Haematology*, **1994**, 88, 201-3	4.5	34
43	The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. *British Journal of Haematology*, **1994**, 88, 845-8	4.5	41
42	Long-term management after splenectomy. Lifelong penicillin unproved in trials. *BMJ: British Medical Journal*, **1994**, 308, 131-2		14
41	Interferon alfa for chronic hepatitis C in haemophiliacs. *Gut*, **1993**, 34, S121-3	19.2	6
40	Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. *Blood*, **1993**, 81, 1898-1902	2.2	67
39	Chronic hepatitis in haemophilia. *Blood Reviews*, **1993**, 7, 243-50	11.1	23
38	Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. *Blood*, **1993**, 81, 1898-902	2.2	8
37	Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. *Blood*, **1993**, 81, 1898-1902	2.2	
36	Need for second-generation anti-HCV testing in haemophilia. *Lancet, The*, **1992**, 339, 501-2	40	7
35	The chest radiograph appearances seen following high dose chemotherapy and autologous bone marrow transplantation for resistant malignant lymphoma. *British Journal of Radiology*, **1991**, 64, 103-6	3.4	2
34	Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B. *Blood Coagulation and Fibrinolysis*, **1991**, 2, 637-41	1	9
33	Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. *Diabetic Medicine*, **1991**, 8, 322-9	3.5	33
32	Bias due to publication of positive results with treatments for thrombotic thrombocytopenic purpura. *Lancet, The*, **1991**, 337, 1106-7	40	3
31	A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. *Blood*, **1991**, 78, 1672-7	2.2	11
30	A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. *Blood*, **1991**, 78, 1672-1677	2.2	70

29	A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. *Blood*, **1991**, 78, 1672-1677	2.2	1
28	Evans' syndrome associated with dermatomyositis. *Annals of the Rheumatic Diseases*, **1990**, 49, 793-4	2.4	3
27	Hepatitis C antibody and chronic liver disease in haemophilia. *Lancet, The*, **1990**, 335, 1117-9	40	204
26	Detection by PCR of hepatitis C virus in factor VIII concentrates. *Lancet, The*, **1990**, 335, 1473	40	35
25	Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. *Lancet, The*, **1990**, 336, 1022-5	40	209
24	Teicoplanin administration in patients experiencing reactions to vancomycin. *Journal of Antimicrobial Chemotherapy*, **1989**, 23, 810-2	5.1	20
23	Basic Principles Underlying the Coagulation System1-7		
22	Von Willebrand Disease51-61		3
21	Qualitative Platelet Disorders83-90		
20	Disseminated Intravascular Coagulation and other Microanjiopathies91-100		
19	Arterial Thrombosis114-119		
18	Anticoagulation120-129		
17	Intensive/Critical Care158-171		
16	Cardiothoracic Surgery172-181		
15	Hepatology182-189		1
14	Transfuction201-208		
13	The Rarer Inherited Coagulation Disorders62-68		
12	Quantitative Platelet Disorders69-82		